| Drug Name |
Mifepristone |
| Drug ID |
BADD_D01463 |
| Description |
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). |
| Indications and Usage |
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery. |
| Marketing Status |
approved; investigational |
| ATC Code |
G03XB01 |
| DrugBank ID |
DB00834
|
| KEGG ID |
D00585
|
| MeSH ID |
D015735
|
| PubChem ID |
55245
|
| TTD Drug ID |
D0Z4EI
|
| NDC Product Code |
44132-005; 44132-013; 65089-0043; 43393-001; 51508-011; 76346-073; 66499-0056; 69989-0003; 60722-3002 |
| UNII |
320T6RNW1F
|
| Synonyms |
Mifepristone | ZK-98296 | ZK 98296 | ZK98296 | R-38486 | R 38486 | RU-486 | RU 486 | RU486 | R38486 | RU-38486 | RU 38486 | RU38486 | Mifegyne | Mifégyne | Mifeprex |
